362 related articles for article (PubMed ID: 30028473)
1. Comparison of the T-cell response to human cytomegalovirus (HCMV) as detected by cytokine flow cytometry and QuantiFERON-CMV assay in HCMV-seropositive kidney transplant recipients.
Gabanti E; Lilleri D; Scaramuzzi L; Zelini P; Rampino T; Gerna G
New Microbiol; 2018 Jul; 41(3):195-202. PubMed ID: 30028473
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of human cytomegalovirus (HCMV) T-cell response in the control of HCMV infection by seropositive solid-organ transplant recipients according to different assays and stimuli.
Gabanti E; Bruno F; Scaramuzzi L; Mangione F; Zelini P; Gerna G; Lilleri D
New Microbiol; 2016 Oct; 39(4):247-258. PubMed ID: 27727404
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
4. Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients.
Lilleri D; Zelini P; Fornara C; Zavaglio F; Rampino T; Perez L; Gabanti E; Gerna G
J Med Virol; 2018 Oct; 90(10):1620-1628. PubMed ID: 29797330
[TBL] [Abstract][Full Text] [Related]
5. ELISPOT assays with pp65 peptides or whole HCMV antigen are reliable predictors of immune control of HCMV infection in seropositive kidney transplant recipients.
Zavaglio F; Rivela F; Cassaniti I; Arena F; Gabanti E; Asti AL; Lilleri D; Rampino T; Baldanti F; Gregorini M
J Med Virol; 2023 Feb; 95(2):e28507. PubMed ID: 36655741
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
8. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.
Calarota SA; Chiesa A; Scaramuzzi L; Adzasehoun KM; Comolli G; Mangione F; Esposito P; Baldanti F
J Clin Virol; 2014 Sep; 61(1):65-73. PubMed ID: 24961915
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
Lee H; Park KH; Ryu JH; Choi AR; Yu JH; Lim J; Han K; Kim SI; Yang CW; Chung BH; Oh EJ
PLoS One; 2017; 12(12):e0189488. PubMed ID: 29232714
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
11. Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: A pilot study.
Martín-Gandul C; Pérez-Romero P; Mena-Romo D; Molina-Ortega A; González-Roncero FM; Suñer M; Bernal G; Cordero E;
Transpl Infect Dis; 2018 Jun; 20(3):e12883. PubMed ID: 29570917
[TBL] [Abstract][Full Text] [Related]
12. Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact.
Valle-Arroyo J; Aguado R; Páez-Vega A; Pérez AB; González R; Fornés G; Torre-Cisneros J; Cantisán S
Sci Rep; 2020 Apr; 10(1):7194. PubMed ID: 32346028
[TBL] [Abstract][Full Text] [Related]
13. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study.
Sund F; Lidehäll AK; Claesson K; Foss A; Tötterman TH; Korsgren O; Eriksson BM
Clin Transplant; 2010; 24(3):401-9. PubMed ID: 19222507
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
Tarasewicz A; Dębska-Ślizień A; Rutkowski B
Transplant Proc; 2016 Jun; 48(5):1650-3. PubMed ID: 27496465
[TBL] [Abstract][Full Text] [Related]
16. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
18. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.
Fernández-Ruiz M; Giménez E; Vinuesa V; Ruiz-Merlo T; Parra P; Amat P; Montejo M; Paez-Vega A; Cantisán S; Torre-Cisneros J; Fortún J; Andrés A; San Juan R; López-Medrano F; Navarro D; Aguado JM;
Clin Microbiol Infect; 2019 Mar; 25(3):381.e1-381.e10. PubMed ID: 29803844
[TBL] [Abstract][Full Text] [Related]
19. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.
Banas B; Böger CA; Lückhoff G; Krüger B; Barabas S; Batzilla J; Schemmerer M; Köstler J; Bendfeldt H; Rascle A; Wagner R; Deml L; Leicht J; Krämer BK
BMC Immunol; 2017 Mar; 18(1):15. PubMed ID: 28270092
[TBL] [Abstract][Full Text] [Related]
20. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.
Lochmanova A; Lochman I; Tomaskova H; Marsalkova P; Raszka J; Mrazek J; Dedochova J; Martinek A; Brozmanova H; Grundmann M
Transplant Proc; 2010 Nov; 42(9):3574-7. PubMed ID: 21094818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]